CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
7.16
1.92%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 7.3
Open* 7.24
1-Year Change* 103.94%
Day's Range* 7.07 - 7.39
52 wk Range 0.65-5.22
Average Volume (10 days) 5.31M
Average Volume (3 months) 30.94M
Market Cap 46.30M
P/E Ratio -100.00K
Shares Outstanding 63.01M
Revenue 25.24M
EPS -1.73
Dividend (Yield %) N/A
Beta 1.63
Next Earnings Date Nov 3, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 27, 2024 7.30 -0.17 -2.28% 7.47 7.89 7.04
Feb 26, 2024 7.42 0.34 4.80% 7.08 7.55 7.08
Feb 23, 2024 7.20 0.18 2.56% 7.02 7.58 6.93
Feb 22, 2024 7.06 0.19 2.77% 6.87 7.12 6.79
Feb 21, 2024 6.97 -0.35 -4.78% 7.32 7.47 6.77
Feb 20, 2024 7.41 0.34 4.81% 7.07 7.61 7.07
Feb 16, 2024 7.15 0.18 2.58% 6.97 7.37 6.87
Feb 15, 2024 7.03 -0.09 -1.26% 7.12 7.12 6.93
Feb 14, 2024 7.07 0.09 1.29% 6.98 7.11 6.63
Feb 13, 2024 6.79 0.07 1.04% 6.72 6.87 6.58
Feb 12, 2024 7.00 -0.04 -0.57% 7.04 7.20 6.88
Feb 9, 2024 7.04 0.07 1.00% 6.97 7.31 6.97
Feb 8, 2024 7.00 -0.13 -1.82% 7.13 7.17 6.82
Feb 7, 2024 7.12 -0.25 -3.39% 7.37 7.42 7.07
Feb 6, 2024 7.36 0.05 0.68% 7.31 7.79 7.17
Feb 5, 2024 7.42 -0.05 -0.67% 7.47 7.55 7.22
Feb 2, 2024 7.59 0.57 8.12% 7.02 7.64 6.97
Feb 1, 2024 7.04 -0.01 -0.14% 7.05 7.21 6.97
Jan 31, 2024 7.06 0.14 2.02% 6.92 7.59 6.92
Jan 30, 2024 6.88 -0.62 -8.27% 7.50 7.55 6.77

Syros Pharma Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total revenue 23.488 15.093 1.982 2.05 1.101
Revenue 23.488 15.093 1.982 2.05 1.101
Total Operating Expense 122.908 97.39 79.723 66.346 55.787
Selling/General/Admin. Expenses, Total 23.036 21.325 21.478 16.164 13.891
Research & Development 99.872 76.065 58.245 50.182 41.896
Operating Income -99.42 -82.297 -77.741 -64.296 -54.686
Other, Net 2.303 2.017 0.676
Net Income Before Taxes -86.558 -84.038 -75.438 -62.279 -54.01
Net Income After Taxes -86.558 -84.038 -75.438 -62.279 -54.01
Net Income Before Extra. Items -86.558 -84.038 -75.438 -62.279 -54.01
Net Income -86.558 -84.038 -75.438 -62.279 -54.01
Total Adjustments to Net Income 0 0
Income Available to Common Excl. Extra. Items -86.558 -84.038 -75.438 -62.279 -54.01
Income Available to Common Incl. Extra. Items -86.558 -84.038 -75.438 -62.279 -54.01
Diluted Net Income -86.558 -84.038 -75.438 -62.279 -54.01
Diluted Weighted Average Shares 62.535 46.0516 40.2222 32.6562 25.4069
Diluted EPS Excluding Extraordinary Items -1.38415 -1.82487 -1.87553 -1.90711 -2.12581
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -1.38415 -1.82487 -1.87553 -1.90711 -2.12581
Interest Income (Expense), Net Non-Operating 12.862 -1.741
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total revenue 5.467 7.802 5.697 5.162 4.827
Revenue 5.467 7.802 5.697 5.162 4.827
Total Operating Expense 32.12 33.225 32.608 31.306 25.768
Selling/General/Admin. Expenses, Total 6.949 6.43 5.346 5.52 5.739
Research & Development 25.171 26.795 27.262 25.786 20.029
Operating Income -26.653 -25.423 -26.911 -26.144 -20.941
Interest Income (Expense), Net Non-Operating 1.507 1.61 0.884 3.654 6.713
Net Income Before Taxes -25.146 -23.813 -26.027 -22.49 -14.228
Net Income After Taxes -25.146 -23.813 -26.027 -22.49 -14.228
Net Income Before Extra. Items -25.146 -23.813 -26.027 -22.49 -14.228
Net Income -25.146 -23.813 -26.027 -22.49 -14.228
Income Available to Common Excl. Extra. Items -25.146 -23.813 -26.027 -22.49 -14.228
Income Available to Common Incl. Extra. Items -25.146 -23.813 -26.027 -22.49 -14.228
Diluted Net Income -25.146 -23.813 -26.027 -22.49 -14.228
Diluted Weighted Average Shares 63.0614 62.9555 62.9283 62.8595 61.3796
Diluted EPS Excluding Extraordinary Items -0.39875 -0.37825 -0.4136 -0.35778 -0.2318
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.39875 -0.37825 -0.4136 -0.35778 -0.2318
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total Current Assets 136.585 178.557 114.513 101.734 73.159
Cash and Short Term Investments 130.369 173.984 91.416 99.679 72.049
Cash & Equivalents 92.302 173.984 41.441 49.886 32.205
Short Term Investments 38.067 0 49.975 49.793 39.844
Total Receivables, Net 2.979 2.331 20.158 0
Accounts Receivable - Trade, Net 2.979 2.331 20.158 0
Prepaid Expenses 3.237 2.242 2.649 1.417 0.917
Total Assets 182.935 213.25 149.978 106.766 78.488
Property/Plant/Equipment, Total - Net 27.285 29.641 31.889 3.861 3.938
Property/Plant/Equipment, Total - Gross 37.141 36.857 36.331 9.163 7.638
Accumulated Depreciation, Total -9.856 -7.216 -4.442 -5.302 -3.7
Other Long Term Assets, Total 6.027 5.052 3.576 1.171 1.391
Total Current Liabilities 31.508 28.624 23.516 19.529 12.413
Accounts Payable 3.692 3.603 5.853 3.309 2.283
Accrued Expenses 17.344 12.547 11.683 13.893 9.728
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.291 0.265 0.241 0.009 0.047
Other Current Liabilities, Total 10.181 12.209 5.739 2.318 0.355
Total Liabilities 97.717 122.697 70.794 28.18 13.164
Total Long Term Debt 40.322 39.907 0.621 0.022 0.006
Capital Lease Obligations 0.065 0.356 0.621 0.022 0.006
Other Liabilities, Total 25.887 54.166 46.657 8.629 0.745
Total Equity 85.218 90.553 79.184 78.586 65.324
Redeemable Preferred Stock 0
Common Stock 0.061 0.056 0.043 0.034 0.026
Additional Paid-In Capital 548.815 467.518 372.1 296.1 220.606
Retained Earnings (Accumulated Deficit) -463.579 -377.021 -292.983 -217.545 -155.266
Other Equity, Total -0.079 0.024 -0.003 -0.042
Total Liabilities & Shareholders’ Equity 182.935 213.25 149.978 106.766 78.488
Total Common Shares Outstanding 62.024 56.2228 43.3678 33.7659 26.4234
Other Current Assets, Total 0.29 0.638 0.193
Preferred Stock - Non Redeemable, Net 0 0
Long Term Debt 40.257 39.551
Long Term Investments 13.038
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total Current Assets 116.477 136.585 153.271 186.207 226.677
Cash and Short Term Investments 110.261 130.369 145.584 182.029 222.142
Cash & Equivalents 69.575 92.302 115.42 160.915 222.142
Short Term Investments 40.686 38.067 30.164 21.114 0
Total Receivables, Net 3.182 2.979 3.632 2.177 2.622
Accounts Receivable - Trade, Net 3.182 2.979 3.632 2.177 2.622
Prepaid Expenses 3.034 3.237 4.055 2.001 1.913
Total Assets 152.081 182.935 208.043 233.734 260.627
Property/Plant/Equipment, Total - Net 26.725 27.285 28.159 28.735 29.121
Other Long Term Assets, Total 6.241 6.027 5.496 5.528 4.829
Total Current Liabilities 27.593 31.508 29.88 27.623 27.369
Accounts Payable 2.841 3.692 4.108 3.671 3.66
Accrued Expenses 15.038 17.344 13.492 11.551 10.652
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 1.941 0.291 0.285 0.278 0.271
Other Current Liabilities, Total 7.773 10.181 11.995 12.123 12.786
Total Liabilities 89.339 97.717 101.983 103.757 110.747
Total Long Term Debt 38.787 40.322 40.212 40.106 40.004
Long Term Debt 38.775 40.257 40.072 39.892 39.718
Capital Lease Obligations 0.012 0.065 0.14 0.214 0.286
Other Liabilities, Total 22.959 25.887 31.891 36.028 43.374
Total Equity 62.742 85.218 106.06 129.977 149.88
Common Stock 0.061 0.061 0.061 0.061 0.061
Additional Paid-In Capital 551.679 548.815 545.77 543.674 541.068
Retained Earnings (Accumulated Deficit) -488.725 -463.579 -439.766 -413.739 -391.249
Total Liabilities & Shareholders’ Equity 152.081 182.935 208.043 233.734 260.627
Total Common Shares Outstanding 62.8013 62.024 61.943 61.9202 61.8496
Long Term Investments 2.638 13.038 21.117 13.264
Other Equity, Total -0.273 -0.079 -0.005 -0.019
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Net income/Starting Line -86.558 -84.038 -75.438 -62.279 -54.01
Cash From Operating Activities -99.54 -57.364 -60.253 -40.315 -44.729
Cash From Operating Activities 3.018 3.035 2.722 1.604 1.527
Non-Cash Items -5.398 11.552 8.709 5.968 4.317
Cash Interest Paid 3.191 1.505 0.072 0.002 0.009
Changes in Working Capital -10.602 12.087 3.754 14.392 3.437
Cash From Investing Activities -52.653 46.664 -11.734 -10.643 -15.591
Capital Expenditures -1.245 -3.336 -12.638 -1.384 -0.821
Other Investing Cash Flow Items, Total -51.408 50 0.904 -9.259 -14.77
Cash From Financing Activities 70.511 142.953 65.99 69.084 33.937
Issuance (Retirement) of Stock, Net 70.817 103.782 66.195 69.134 34.105
Issuance (Retirement) of Debt, Net -0.265 39.378 -0.205 -0.05 -0.168
Net Change in Cash -81.682 132.253 -5.997 18.126 -26.383
Cash Taxes Paid 0 0.007 0.029
Financing Cash Flow Items -0.041 -0.207
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -25.146 -86.558 -62.745 -36.718 -14.228
Cash From Operating Activities -30.017 -99.54 -76.571 -48.444 -21.99
Cash From Operating Activities 0.747 3.018 2.245 1.48 0.731
Non-Cash Items 0.676 -5.398 -5.995 -6.537 -4.573
Cash Taxes Paid 0 0 0 0
Cash Interest Paid 0.783 3.191 2.38 1.585 0.789
Changes in Working Capital -6.294 -10.602 -10.076 -6.669 -3.92
Cash From Investing Activities 7.383 -52.653 -52.408 -35.107 -0.262
Capital Expenditures -0.128 -1.245 -1 -0.69 -0.262
Other Investing Cash Flow Items, Total 7.511 -51.408 -51.408 -34.417 0
Cash From Financing Activities -0.093 70.511 70.415 70.482 70.41
Financing Cash Flow Items -0.024 -0.041 -0.036 -0.036 -0.036
Issuance (Retirement) of Stock, Net 0.001 70.817 70.647 70.647 70.51
Issuance (Retirement) of Debt, Net -0.07 -0.265 -0.196 -0.129 -0.064
Net Change in Cash -22.727 -81.682 -58.564 -13.069 48.158

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Syros Pharma Company profile

About Syros Pharmaceuticals Inc

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on redefending the power of small molecules to control the expression of genes. The Company is engaged in developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical stage pipeline of gene control medicine. Its lead product candidates include SY-1425, SY-2101 and SY-5609. Its SY-1425, is a selective retinoic acid receptor alpha (RARα) that is being evaluated in combination with azacytidine used to treat acute myeloid leukemia (AML). Its SY-2101, a novel oral form of arsenic trioxide (ATO) being developed for the treatment of AML. Its SY-5609, is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) that is being evaluated in the dose escalation portion in patients with select advanced solid tumors.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Syros Pharmaceuticals Inc revenues increased 56% to $23.5M. Net loss increased 3% to $86.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research & Development - Balancing value increase of 33% to $70M (expense), Labor & Related Expenses in R&D increase of 30% to $24.2M (expense).

Industry: Biotechnology & Medical Research (NEC)

35 Cambridge Park Drive
02140

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

Gold

2,036.03 Price
+0.290% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0109%
Overnight fee time 22:00 (UTC)
Spread 0.30

BTC/USD

61,361.65 Price
+8.090% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Oil - Crude

78.28 Price
-0.100% 1D Chg, %
Long position overnight fee 0.0219%
Short position overnight fee -0.0439%
Overnight fee time 22:00 (UTC)
Spread 0.030

US100

17,862.90 Price
-0.580% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading